JP2013523677A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523677A5 JP2013523677A5 JP2013501780A JP2013501780A JP2013523677A5 JP 2013523677 A5 JP2013523677 A5 JP 2013523677A5 JP 2013501780 A JP2013501780 A JP 2013501780A JP 2013501780 A JP2013501780 A JP 2013501780A JP 2013523677 A5 JP2013523677 A5 JP 2013523677A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- levan
- solvent
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- AIHDCSAXVMAMJH-GFBKWZILSA-N Levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 claims 8
- 239000004480 active ingredient Substances 0.000 claims 7
- 239000002904 solvent Substances 0.000 claims 7
- 210000003296 Saliva Anatomy 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 238000002360 preparation method Methods 0.000 claims 6
- 239000011159 matrix material Substances 0.000 claims 5
- 239000007788 liquid Substances 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- XUFQPHANEAPEMJ-UHFFFAOYSA-N Famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims 2
- 229960001596 Famotidine Drugs 0.000 claims 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N Loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims 2
- 229960003088 Loratadine Drugs 0.000 claims 2
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims 2
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 claims 2
- 229960005343 Ondansetron Drugs 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 229960005127 montelukast Drugs 0.000 claims 2
- 238000000859 sublimation Methods 0.000 claims 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 claims 1
- 229960002845 Desmopressin Acetate Drugs 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N Raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- NFLWUMRGJYTJIN-PNIOQBSNSA-N desmopressin Chemical group C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-PNIOQBSNSA-N 0.000 claims 1
- 229960004281 desmopressin Drugs 0.000 claims 1
- YNKFCNRZZPFMEX-XHPDKPNGSA-N desmopressin acetate trihydrate Chemical group O.O.O.CC(O)=O.C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 YNKFCNRZZPFMEX-XHPDKPNGSA-N 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 239000002075 main ingredient Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000007892 solid unit dosage form Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Claims (22)
- 薬学的に活性な成分を担持するマトリックスを含み、マトリックス形成剤としてレバンを含む医薬組成物。
- レバンがマトリックス形成主剤である、請求項１に記載の医薬組成物。
- マトリックスがレバン及びマンニトールを含む、請求項１又は２に記載の医薬組成物。
- マトリックスがレバン及びトレハロースを含む、請求項１又は２に記載の医薬組成物。
- マトリックスがレバン及びラフィノースを含む、請求項１又は２に記載の医薬組成物。
- 組成物の少なくとも８０％が、水性媒体又は唾液に、３０秒以内に溶解する、請求項１から５のいずれか１項に記載の医薬組成物。
- 組成物の少なくとも８０％が、水性媒体又は唾液に、１０秒以内に溶解する、請求項６に記載の医薬組成物。
- 約０．０５〜１．６Ｎ／ｍｍ2の引張り強さ、及び、組成物の少なくとも８０％が水性媒体又は唾液に３０秒以内に溶解する迅速な溶解速度を有する、薬学的に活性な成分を含む医薬組成物。
- 組成物が、水性媒体又は唾液に、１０秒以内に溶解する、請求項８に記載の医薬組成物。
- 経口剤形である請求項１から９のいずれか１項に記載の医薬組成物。
- 舌下投与されるようになっている、請求項１０に記載の医薬組成物。
- 活性成分及びレバンを溶媒中に含む液体調製物から溶媒を昇華させることによって得ることができる、請求項１から１１のいずれか１項に記載の医薬組成物。
- 昇華が、前記調製物を凍結乾燥することによって実施される、請求項１２に記載の医薬組成物。
- 活性成分が酢酸デスモプレシン、ロラチジン、ファモチジン、モンテルカスト及びオンダンセトロンからなる群より選ばれる、請求項１から１３のいずれか１項に記載の医薬組成物。
- 薬学的に活性な成分及びレバンを溶媒中に含む液体調製物から溶媒を昇華させることを含む、医薬組成物の調製方法。
- （ａ）単位投与量の前記液体調製物を、カバーされていないブリスターパックの凹部に導入すること；及び（ｂ）前記凹部内に固体単位剤形を得るために、調製物を昇華させること；を含む、請求項１５に記載の方法。
- 昇華が、調製物を凍結乾燥することによって実施される、請求項１６に記載の方法。
- 溶媒が水である、請求項１５に記載の方法。
- 活性成分がデスモプレシン、ロラチジン、ファモチジン、モンテルカスト及びオンダンセトロンからなる群より選ばれる、請求項１５から１８のいずれか１項に記載の方法。
- （ａ）レバン及び活性成分を溶媒中に含む溶液を調製すること；
（ｂ）前記溶液を凍結すること；
（ｃ）凍結した溶液から溶媒を昇華させること；
を含み、そうして得られる医薬組成物が、水溶液又は唾液との接触で、３０秒以内に崩壊する、医薬組成物の調製方法。 - 医薬組成物が、水溶液又は唾液との接触で、１０秒以内に崩壊する、請求項２０に記載の方法。
- 組成物が、請求項１から１４のいずれか１項に記載の組成物である、請求項２０又は２１に記載の方法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN743DE2010 | 2010-03-29 | ||
| IN743/DEL/2010 | 2010-03-29 | ||
| PCT/EP2011/054699 WO2011120904A2 (en) | 2010-03-29 | 2011-03-28 | A fast dissolving pharmaceutical composition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013523677A JP2013523677A (ja) | 2013-06-17 |
| JP2013523677A5 true JP2013523677A5 (ja) | 2014-04-24 |
| JP5736031B2 JP5736031B2 (ja) | 2015-06-17 |
Family
ID=44169174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501780A Active JP5736031B2 (ja) | 2010-03-29 | 2011-03-28 | 速溶解性医薬組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US8946153B2 (ja) |
| EP (1) | EP2552418B1 (ja) |
| JP (1) | JP5736031B2 (ja) |
| KR (1) | KR101790188B1 (ja) |
| CN (2) | CN104606128B (ja) |
| AR (1) | AR080735A1 (ja) |
| AU (1) | AU2011234637B2 (ja) |
| BR (1) | BR112012024432A2 (ja) |
| CA (1) | CA2793485A1 (ja) |
| ES (1) | ES2643087T3 (ja) |
| IL (2) | IL222087A (ja) |
| MX (2) | MX341200B (ja) |
| NZ (3) | NZ619857A (ja) |
| PL (1) | PL2552418T3 (ja) |
| RU (1) | RU2566269C2 (ja) |
| SA (1) | SA111320320B1 (ja) |
| TW (1) | TWI498132B (ja) |
| WO (1) | WO2011120904A2 (ja) |
| ZA (1) | ZA201207175B (ja) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8318817B2 (en) | 2008-07-21 | 2012-11-27 | Otonomy, Inc. | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
| JO3112B1 (ar) | 2010-03-29 | 2017-09-20 | Ferring Bv | تركيبة دوائية سريعة التحلل |
| NZ619857A (en) | 2010-03-29 | 2015-05-29 | Ferring Bv | A fast dissolving pharmaceutical composition |
| KR20140061438A (ko) * | 2011-09-16 | 2014-05-21 | 훼링 비.브이. | 속용성 약학 조성물 |
| JP6259454B2 (ja) | 2012-07-12 | 2018-01-10 | フェリング ベスローテン フェンノートシャップ | ジクロフェナク製剤 |
| TW201422254A (zh) * | 2012-11-21 | 2014-06-16 | Ferring Bv | 用於速釋及延釋的組成物 |
| WO2015063602A1 (en) * | 2013-10-29 | 2015-05-07 | Ferring B.V. | Desmopressin and blood glucose |
| EP3320908B1 (en) * | 2015-07-07 | 2023-09-06 | Toa Pharmaceutical Co., Ltd. | Bacteria-containing oral rapidly disintegrating tablet |
| US10172833B2 (en) | 2015-08-11 | 2019-01-08 | Insys Development Company, Inc. | Sublingual ondansetron spray |
| WO2017075554A1 (en) * | 2015-10-29 | 2017-05-04 | Golfetto Michael | Methods freeze drying and composite materials |
| RU2751193C2 (ru) | 2017-01-11 | 2021-07-12 | Ферринг Б.В. | Быстро распадающаяся фармацевтическая композиция |
| JP2022508714A (ja) | 2018-10-15 | 2022-01-19 | アプレシア・ファーマスーティカルズ・エルエルシー | 包装内に剤形を形成する方法およびシステム |
| CN113750058B (zh) * | 2020-06-01 | 2023-07-04 | 北京九能天远科技有限公司 | 一种间苯三酚冻干口崩片及其制备方法 |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| CN114010609A (zh) * | 2021-11-23 | 2022-02-08 | 莱默(北京)药业科技有限公司 | 一种孟鲁司特钠冻干口崩片及制备方法 |
| WO2024144674A1 (en) * | 2022-12-26 | 2024-07-04 | Atatürk Üni̇versi̇tesi̇ Fi̇kri̇ Mülki̇yet Haklari Koordi̇natörlüğü Döner Sermaye İşletmesi̇ | Orally disintegrating (odt) tablets formulations containing indomethacin and famotidine |
| WO2024150261A1 (en) * | 2023-01-10 | 2024-07-18 | Zarqa University | An oral pharmaceutical formulation and a method of preparation thereof |
| DE102023200788A1 (de) | 2023-01-31 | 2024-08-01 | Technische Universität Braunschweig - Körperschaft des öffentlichen Rechts | Festes Lyophilisat und Verfahren zur Herstellung |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| JPS5446841A (en) * | 1977-08-16 | 1979-04-13 | Wellcome Found | Drug substituted hapten substance and production thereof |
| CN1053808C (zh) | 1993-04-24 | 2000-06-28 | 章修纲 | 尼非地平控释剂型 |
| AU4052997A (en) | 1996-07-19 | 1998-02-10 | Clarke-Garegg, Margaret A. | Levan derivatives, their preparation, composition and applications including medical and food applications |
| TW362041B (en) * | 1996-12-27 | 1999-06-21 | Asahi Chemical Ind | Leakage inspection apparatus and method for filter film |
| EP0879600A1 (en) * | 1997-05-20 | 1998-11-25 | Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) | Fructan containing composition for the prevention and treatment of colon cancer |
| EP0958825A1 (en) | 1998-05-18 | 1999-11-24 | Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) | Synergistic composition of a non-digestible carbohydrate and an anti-cancer drug for use in the treatment of cancer |
| SE9803871D0 (sv) | 1998-11-11 | 1998-11-11 | Pharmacia & Upjohn Ab | Therapeutic method and formulation |
| WO2000025754A2 (en) | 1998-11-04 | 2000-05-11 | Mcneil-Ppc, Inc. | Solid oral dosage forms containing alginic acid and famotidine |
| GB9901819D0 (en) | 1999-01-27 | 1999-03-17 | Scherer Corp R P | Pharmaceutical compositions |
| GB9908014D0 (en) | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| NL1012300C2 (nl) | 1999-06-11 | 2000-12-12 | Rijksuniversiteit | Stabilisator voor farmaca. |
| EP1064938A1 (en) | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Pharmaceutical dosage forms for controlled release producing at least a timed pulse |
| EP1202716A1 (en) | 1999-08-17 | 2002-05-08 | Novartis Consumer Health S.A. | Rapidly dissolving dosage form and process for making same |
| WO2002003992A2 (en) | 2000-07-06 | 2002-01-17 | Wyeth | Use of substituted indole compounds for treating prosthesis-related bone degeneration |
| EP1308171A1 (en) | 2000-07-13 | 2003-05-07 | Daiichi Pharmaceutical Co., Ltd. | Pharmaceutical compositions containing dds compounds |
| US6509040B1 (en) * | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
| MY148466A (en) | 2001-10-26 | 2013-04-30 | Merck Frosst Canada Ltd | Granule formulation |
| MXPA04009673A (es) | 2002-04-03 | 2005-01-11 | Solvay Pharm Bv | Formulacion de cannabinoide natural estabilizado. |
| WO2003094886A2 (en) * | 2002-05-07 | 2003-11-20 | Ferring Bv | Desmopressin in an orodispersible dosage form |
| GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
| US20040096569A1 (en) * | 2002-11-15 | 2004-05-20 | Barkalow David G. | Edible film products and methods of making same |
| EP1428526A1 (en) * | 2002-12-13 | 2004-06-16 | Rijksuniversiteit Groningen | Formulation for fast dissolution of lipophilic compounds |
| US8012505B2 (en) | 2003-02-28 | 2011-09-06 | Alk-Abello A/S | Dosage form having a saccharide matrix |
| WO2004075875A1 (en) | 2003-02-28 | 2004-09-10 | Alk-Abello A/S | Dosage form having a saccharide matrix |
| ES2300546T3 (es) * | 2003-09-05 | 2008-06-16 | Myung-Jun Chung | Polvo de bacterias del acido lactico doblemente recubiertas usando proteina y polisacarido y metodo de preparacion del mismo y forma farmaceutica del mismo. |
| CN100366294C (zh) | 2004-04-30 | 2008-02-06 | 量子高科（北京）研究院有限公司 | 一种口腔速溶制剂及其生产方法 |
| EP1597978A1 (en) * | 2004-05-17 | 2005-11-23 | Nutricia N.V. | Synergism of GOS and polyfructose |
| CN100339081C (zh) * | 2004-11-10 | 2007-09-26 | 范敏华 | 一种氯雷他定口腔崩解片剂的制备方法 |
| JP2008525420A (ja) * | 2004-12-23 | 2008-07-17 | マクニール−ピーピーシー・インコーポレーテツド | 感覚的きっかけ剤を有する、口で崩壊する薬用組成物 |
| US20070042023A1 (en) * | 2005-08-22 | 2007-02-22 | National Starch And Chemical Investment Holding Corporation | Dissolvable film |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| US8067237B2 (en) * | 2005-12-13 | 2011-11-29 | President And Fellows Of Harvard College | Scaffolds for cell transplantation |
| TW200817049A (en) | 2006-06-05 | 2008-04-16 | Verus Pharmaceuticals Inc | Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms |
| CN101636173A (zh) * | 2007-03-27 | 2010-01-27 | 宝洁公司 | 施用益生菌剂的方法及试剂盒 |
| CN101686942B (zh) | 2007-06-27 | 2012-09-26 | 韩美药品株式会社 | 用于快速制备用于口服的崩解剂的方法及其产品 |
| KR100930427B1 (ko) * | 2008-01-25 | 2009-12-08 | 정명준 | 3중 코팅 유산균의 제조방법 및 나노 입자 코팅 방법, 그방법으로 제조된 3중 코팅 유산균 및 이를 포함하는 제품 |
| US8623401B2 (en) * | 2008-03-27 | 2014-01-07 | Fenwafe Inc. | Wafer formulation |
| NZ619857A (en) | 2010-03-29 | 2015-05-29 | Ferring Bv | A fast dissolving pharmaceutical composition |
| US20120135050A1 (en) | 2010-07-08 | 2012-05-31 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
-
2011
- 2011-03-28 NZ NZ619857A patent/NZ619857A/en not_active IP Right Cessation
- 2011-03-28 KR KR1020127027214A patent/KR101790188B1/ko active IP Right Grant
- 2011-03-28 US US13/636,758 patent/US8946153B2/en active Active
- 2011-03-28 CN CN201510034145.8A patent/CN104606128B/zh active Active
- 2011-03-28 TW TW100110571A patent/TWI498132B/zh active
- 2011-03-28 CA CA2793485A patent/CA2793485A1/en not_active Abandoned
- 2011-03-28 MX MX2012011205A patent/MX341200B/es active IP Right Grant
- 2011-03-28 CN CN201180017614.5A patent/CN102834091B/zh active Active
- 2011-03-28 JP JP2013501780A patent/JP5736031B2/ja active Active
- 2011-03-28 MX MX2016007895A patent/MX350447B/es unknown
- 2011-03-28 EP EP11711321.7A patent/EP2552418B1/en active Active
- 2011-03-28 AU AU2011234637A patent/AU2011234637B2/en not_active Ceased
- 2011-03-28 BR BR112012024432A patent/BR112012024432A2/pt not_active IP Right Cessation
- 2011-03-28 ES ES11711321.7T patent/ES2643087T3/es active Active
- 2011-03-28 PL PL11711321T patent/PL2552418T3/pl unknown
- 2011-03-28 WO PCT/EP2011/054699 patent/WO2011120904A2/en active Application Filing
- 2011-03-28 NZ NZ602442A patent/NZ602442A/en not_active IP Right Cessation
- 2011-03-28 RU RU2012141140/15A patent/RU2566269C2/ru not_active IP Right Cessation
- 2011-03-28 NZ NZ706991A patent/NZ706991A/en not_active IP Right Cessation
- 2011-03-29 AR ARP110101022A patent/AR080735A1/es unknown
- 2011-03-29 SA SA111320320A patent/SA111320320B1/ar unknown
-
2012
- 2012-09-23 IL IL222087A patent/IL222087A/en not_active IP Right Cessation
- 2012-09-25 ZA ZA2012/07175A patent/ZA201207175B/en unknown
-
2013
- 2013-07-26 US US13/952,084 patent/US9096335B2/en active Active
-
2014
- 2014-12-16 US US14/571,883 patent/US10023335B2/en active Active
-
2016
- 2016-08-02 IL IL247079A patent/IL247079A0/en unknown
-
2018
- 2018-06-16 US US16/010,412 patent/US20180297728A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013523677A5 (ja) | ||
| JP2013523676A5 (ja) | ||
| RU2014105585A (ru) | Быстрорастворимая фармацевтическая композиция | |
| RU2012141140A (ru) | Быстрорастворимая фармацевтическая композиция | |
| JP2016501828A5 (ja) | ||
| JP2016065086A5 (ja) | ||
| PE20181177A1 (es) | Formas de dosis de liberacion controlada encerradas resistentes a manipulaciones indebidas | |
| JP2012255026A5 (ja) | ||
| RU2012141141A (ru) | Быстрорастворимая фармацевтическая композиция | |
| JP2013518107A5 (ja) | ||
| EA201200096A1 (ru) | Фармацевтическая композиция ингибитора протеазы вируса гепатита c | |
| PE20091184A1 (es) | Formas de dosificacion farmaceutica | |
| JP2007506775A5 (ja) | ||
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| JP2012530141A5 (ja) | ||
| JP2013542247A5 (ja) | ||
| JP2014129360A5 (ja) | ||
| JP2012502037A5 (ja) | ||
| JP2014221827A5 (ja) | ||
| JP2016540021A5 (ja) | ||
| JP2014218522A5 (ja) | ||
| AR076864A1 (es) | Procedimiento y composicion para mejorar la absorcion de agentes terapeuticos | |
| JP2015535243A5 (ja) | ||
| JP2011527299A5 (ja) | ||
| EA201400679A1 (ru) | Композиция сухого порошка производного азола для ингаляции |